Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. - Wikidata - awgldk - TriplyDB

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

http://www.wikidata.org/entity/Q36099235

about

Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses Universal influenza vaccines, a dream to be realized soon.Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Influenza vaccines based on virus-like particles Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.Virus-like particles as universal influenza vaccines Purification of functional baculovirus particles from silkworm larval hemolymph and their use as nanoparticles for the detection of human prorenin receptor (PRR) binding.A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity.HIV p24 as scaffold for presenting conformational HIV Env antigens.Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.Plant-based vaccines against viruses.Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs.Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments in virus-like particle-based vaccines for HIV.Applications of nanotechnology for immunology.VLPs and particle strategies for cancer vaccines.Dense Array of Spikes on HIV-1 Virion Particles.Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine.Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.Nanoparticle Vaccines Against Infectious Diseases

P2860

Q26777740-FD68E379-8FBD-4090-921C-0EFA5419F3E5 Q28365124-335F9A4C-8190-42DB-9D05-CEA8354EE3A2 Q30361950-6869BDD8-0F59-4D25-B729-103A978F655A Q30372024-BED9FD04-BE2C-42CA-942F-D70806E05F07 Q30375784-BA60B986-7A8D-4264-9615-7F421D3B2925 Q30376236-01BA359C-1C5B-4DC7-9C57-A720E9919711 Q30393406-8ACA5312-191A-4F02-B271-28FF5C7851FE Q30421558-C8FBACDF-35E6-4CBD-B859-4CEB8D028579 Q33920192-154F6169-B07C-4EAF-AE49-0456A4566571 Q34005516-FBC9BF88-9E1D-4166-A068-017980E9B1AE Q34389522-7FFA069D-CBDE-40E2-B9FF-8E18063A2022 Q34576055-96D435D3-5DA2-4560-AD54-F11FA2110DBE Q34687464-7E8EF11C-E515-4371-A18A-B9EA20655945 Q35140889-9AA9FD86-E168-46CF-8C41-F7BB10BB4FE8 Q35232804-04F895C2-698E-4AA3-92A9-A87E74E1E261 Q35824686-8161564B-02F5-4D44-B4EE-18342DFA73D8 Q36673724-DEAA854F-3B5A-4192-87C5-177F3177E498 Q36944911-AD34087C-FA3C-41A8-9D31-022F3DD44940 Q37018558-8CF35D3D-4C99-4912-AFB6-84B45FD8EF19 Q37516075-6A5D4F59-D59F-4DFA-8021-B48A9A3F6A9C Q37627859-D59703BC-6D87-4B96-AE07-3CF55473FE35 Q37834097-6A0C448B-01F2-4207-981E-0789513F03D2 Q37951525-C5C4E7DD-D047-406D-88F0-31FAEF9B6039 Q38081965-8947A666-8216-4941-A69A-EE9AE9F01B79 Q38123937-B2DA02A6-5B19-444B-B60F-9338ACCBCCD4 Q38152475-881F2E6A-F5F2-495F-984A-30E100DE6604 Q38817990-C3D54111-2406-4E70-A771-07640A343100 Q38822536-ECBFABFA-3AC1-4027-B30C-D829E7124601 Q39427650-30A91239-4984-4290-98FF-984AB2B43A43 Q40579418-9C8620F3-21AD-4734-877F-7CBFEDB817AA Q40659603-BF11DCD2-2E49-43DB-93D2-DFE9BDDC8BCD Q42140292-BF9F97DC-B63E-432E-9DC8-38D12CD9AA5F Q42197619-DF3B3590-4988-4677-A041-5F58711F967F Q42360336-262EFD26-409E-4EC0-BE02-C19E8486524E Q54207383-579C3CB4-4B1E-436E-9F2E-824717BC01AF Q55433971-F2EAE086-4BC2-4567-927C-804627AC6A85 Q58583890-B4854A74-6060-4267-ADDD-15DDAD81EC56

P2860

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.

http://www.wikidata.org/entity/Q36099235

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Incorporation of high levels o ...... ins into virus-like particles.

@ast

Incorporation of high levels o ...... ins into virus-like particles.

@en

type

label

Incorporation of high levels o ...... ins into virus-like particles.

@ast

Incorporation of high levels o ...... ins into virus-like particles.

@en

prefLabel

Incorporation of high levels o ...... ins into virus-like particles.

@ast

Incorporation of high levels o ...... ins into virus-like particles.

@en

P1433

Q36099235-1BE853F4-1140-416A-A1C3-7718047F9534

P1476

Q36099235-BFD5DBB8-419B-4598-B85F-15DA0CBD0BA1

P2093

Q36099235-01FB39E6-C150-4F08-B862-40500784BEEB

Q36099235-06FF451D-65EA-4BFE-A958-D2337408D1AE

Q36099235-0758295C-38D6-45AA-9081-AB2192ACE682

Q36099235-2732C883-7513-481A-806A-3FC8241874D7

Q36099235-6AF147D9-72CD-4749-8FF2-9AF18B908C08

Q36099235-79B5A31D-475E-4FFF-A1AE-9810B61136AD

Q36099235-99C21B4C-A685-4261-88C5-F14DDE48D843

Q36099235-C0BE6B53-6CF0-4E91-9B17-9B7EABBEF14A

Q36099235-CC38C6B4-DE09-4760-A3FC-DCBB8F46E72F

Q36099235-ECDA343D-306C-4FEF-8702-DAAF41592F1C

P2860

Q36099235-1363DF31-E221-4A1A-BB70-283FF5FD45B1

Q36099235-29812E3F-7694-412D-AE55-FFE8A1EB908E

Q36099235-33547E49-D6E2-4E19-9FE9-1665507047A0

Q36099235-37F98AA6-8F65-4F2D-ACB2-7411015B42F8

Q36099235-4299423E-A97F-4751-A3F4-8CDC706BD2D4

Q36099235-556930B4-F6F9-491D-A0AA-1BC124235A3C

Q36099235-5F425C37-564D-4979-974D-944F017549CB

Q36099235-692C1375-3D47-470A-89BE-D950ACA4D4B5

Q36099235-7184BE4C-17D9-4C52-8344-A879D9765FF6

Q36099235-74346CB7-E6B4-4069-83BD-A1CC46BCFDBE

P304

Q36099235-0EC45C80-5F70-44B7-A900-F8E7CB3F7069

P31

Q36099235-6B3161C3-266B-44B7-A5C9-665BBD51EB28

P356

Q36099235-219BDEAB-18D9-4E26-AADD-0D554F41496E

P407

Q36099235-E436FBD8-E813-4352-AA66-FDE071FF1317

P433

Q36099235-5E15C91E-1CC4-42EE-A68A-7954AF2AE485

P478

Q36099235-3FC9D374-BCDE-4C5F-BD88-ECC6DD93DA84

P50

Q36099235-4C0EB003-CAE9-4535-87DF-7763608540DF

Q36099235-5E993DC4-6096-429D-9184-0D46A1288E6C

Q36099235-C6883FB8-1420-4A21-8694-E8080E580E44

Q36099235-E57A8935-11B3-4BA6-8F4E-EA94E7E78C6B

P577

Q36099235-E0FFF7E8-C94F-4F72-B7F6-6B5F46E88E70

P698

Q36099235-49C48150-F2BB-4625-A885-D160729F8C52

P932

Q36099235-09D74E04-94CB-4A88-98A4-B6FE85D566D4

P356

P1433

Journal of Virology

P1476

Incorporation of high levels o ...... ins into virus-like particles.

@en

P2093

Chunzi Huang

http://www.w3.org/2001/XMLSchema#string

Denise L Kothe

http://www.w3.org/2001/XMLSchema#string

Gale Smith

http://www.w3.org/2001/XMLSchema#string

Ling Ye

http://www.w3.org/2001/XMLSchema#string

Munir Alam

http://www.w3.org/2001/XMLSchema#string

Peter Pushko

http://www.w3.org/2001/XMLSchema#string

Sang-Moo Kang

http://www.w3.org/2001/XMLSchema#string

Terje Dokland

http://www.w3.org/2001/XMLSchema#string

Weimin Liu

http://www.w3.org/2001/XMLSchema#string

Yingying Li

http://www.w3.org/2001/XMLSchema#string

P2860

Point Mutations in the HIV-1 Matrix Protein Turn Off the Myristyl Switch

Site-directed mutagenesis by overlap extension using the polymerase chain reaction

Genetics of mouse mammary tumor virus-induced mammary tumors: linkage of tumor induction to the gag gene.

Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization.

Viral late domains

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

Virus-like particle and DNA-based candidate AIDS vaccines.

Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses

P304

10869-10878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00542-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

Richard W. Compans

Beatrice H. Hahn

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17670815

http://www.w3.org/2001/XMLSchema#string

P932

2045522

http://www.w3.org/2001/XMLSchema#string